drugset / Trial / NCT00719693

Assessment of the Effect of Food on ABT-143 Bioavailability

NCT00719693 ↗

Phase 1 Completed 115 enrolled AstraZeneca
RandomizedCrossoverOpen-labelBasic science

Summary

Single-dose, open-label, two-period crossover study of ABT-143

Timeline

Start
2008-07
Primary completion
2008-09
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Rosuvastatin Small molecule — —
Subject fenofibric acid Small molecule — —

Indications

No indication recorded.